ArticleNature communications2021
Antibody-guided in vivo imaging of Aspergillus fumigatus lung infections during antifungal azole treatment.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05860387 (Early Diagnosis of Invasive Lung Aspergillosis), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Diagnosis of Invasive Lung Aspergillosis
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Mechanistic Insights Into Acute Kidney Injury Complicating Invasive Pulmonary Aspergillosis in Adults.Cureus · 2026Review
- Recent advances in multimodal imaging of infections: research highlights using Nuclear-Optical imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- Review
- Fungal infections in focus: accelerating non-invasive imaging from preclinical insights to clinical breakthroughs.Npj imaging · 2025Review
- Observational
- Pulmonary Aspergillosis Mimicking Metastatic RCC: A Postnephrectomy Diagnostic Consideration.Case reports in medicine · 2025Article
- PET imaging of Aspergillus infection using Zirconium-89 labeled anti-β-glucan antibody fragments.European journal of nuclear medicine and molecular imaging · 2024Article
- Polyene-Based Derivatives with Antifungal Activities.Pharmaceutics · 2024Review
- Establishing a pulmonary aspergillus fumigatus infection diagnostic platform based on RPA-CRISPR-Cas12a.World journal of microbiology & biotechnology · 2024Article
- Recent Advancements in Radiopharmaceuticals for Infection Imaging.Methods in molecular biology (Clifton, N.J.) · 2024Review
- The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Targeting Aspergillus allergen oryzin with a chemical probe at atomic precision.Scientific reports · 2023Article
- Radiotracer Development for Fungal-Specific Imaging: Past, Present, and Future.The Journal of infectious diseases · 2023Review
- The Promise of Molecular Imaging: Focus on Central Nervous System Infections.The Journal of infectious diseases · 2023Review
- Assessment of Antifungal Pharmacodynamics.Journal of fungi (Basel, Switzerland) · 2023Article
- Radiometal chelators for infection diagnostics.Frontiers in nuclear medicine · 2023Article
- Dynamic full-field optical coherence tomography for live-cell imaging and growth-phase monitoring inFrontiers in cellular and infection microbiology · 2023Article
- Novel Treatment Approach for Aspergilloses by Targeting Germination.Journal of fungi (Basel, Switzerland) · 2022Review
- Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives.International journal of molecular sciences · 2022Review
- Novel Insights intoJournal of fungi (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease of immunocompromised humans, caused by the opportunistic fungal pathogen Aspergillus fumigatus. Inadequacies in current diagnostic procedures mean that early diagnosis of the disease, critical to patient survival, remains a major clinical challenge, and is leading to the empiric use of antifungal drugs and emergence of azole resistance. A non-invasive procedure that allows both unambiguous detection of IPA and its response to azole treatment is therefore needed. Here, we show that a humanised Aspergillus-specific monoclonal antibody, dual labelled with a radionuclide and fluorophore, can be used in immunoPET/MRI in vivo in a neutropenic mouse model and 3D light sheet fluorescence microscopy ex vivo in the infected mouse lungs to quantify early A. fumigatus lung infections and to monitor the efficacy of azole therapy. Our antibody-guided approach reveals that early drug intervention is critical to prevent complete invasion of the lungs by the fungus, and demonstrates the power of molecular imaging as a non-invasive procedure for tracking IPA in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.